Transforming Technology for Drug Discovery
HOME ABOUT US TECHNOLOGY OUR SERVICE PUBLICATIONS CONTACT US

Ligandomics technology was recently published in the prestigious Journal of Experimental Medicine

Secretogranin III as a disease-associated ligand for anti-angiogenic therapy of diabetic retinopathy. J. Exp. Med. 214(4):1029-1047

The innovation and breakthrough nature of this approach are highlighted by the press release from the Journal at http://www.newswise.com/articles/view/671627/?sc=rsin.

 

 

© Copyright LigandomicsRx. All rights reserved.